Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak |
| |
Institution: | 1. Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt;2. Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt;3. Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38107, USA;4. Human Link, Dubai, UAE |
| |
Abstract: | The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed. |
| |
Keywords: | SARS-CoV-2 COVID-19 pandemic Neutralizing antibodies Microneutralization assay SARS-CoV-2 vaccine Vaccine effectiveness |
本文献已被 ScienceDirect 等数据库收录! |
|